Axillary Dissection — The Bell Tolls for Thee
Mené sur 2 766 patientes atteintes d'un cancer du sein de stade T1 à T3 et présentant une ou deux macrométastases au ganglion sentinelle (durée médiane de suivi : 46,8 mois), cet essai randomisé international de phase III évalue la possibilité, du point de vue de la survie globale, d'omettre le curage complet des ganglions axillaires après une biopsie du ganglion sentinelle
The reliance on axillary-lymph-node dissection in the management of breast cancer has evolved over time. Although axillary-lymph-node dissection was long considered to be the standard of care for axillary staging, sentinel-node biopsy emerged in the mid-1990s as an alternative to axillary-lymph-node dissection for patients with clinically node-negative breast cancer. Over the next decade, at least two randomized trials supported sentinel-node biopsy as the standard for axillary staging in patients with node-negative disease,1,2 and this approach was eventually adopted worldwide. However, axillary-lymph-node dissection remained the standard of care for patients who had positive results on sentinel-node biopsy for the purposes of . . .